Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Tailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations
Elghazaly, Hesham , Azim, Hamdy A., Curigliano, Giuseppe , Tripathy, Debu , Arun, Banu , Aapro, Matti , Piccart, Martine , Elghazawy, Hagar , Saghir, Nagi S. El , Perez, Edith A. , Poortmans, Philip , Abdel-Aziz, Hany, El‐Zawahry, Heba M., Sabry, Mohamed , Viale, Giuseppe , Gado, Neven, Leung, James , El-Arab, Lobna Ezz, Cardoso, Maria João , Al‐Foheidi, Meteb , ElMaadawy, Merit, Selim, Ashraf S. M., Kandil, Alaa , Kamal, Rasha Mohammed, Guarneri, Valentina , Abulkhair, Omalkhair , Zakaria, Omar, Golshan, Mehra, Orecchia, Roberto , El-Mahdy, Manal Mohamed, Abdel‐Aziz, Ahmed M., Eldin, Nermean Bahie, Curigliano, Giuseppe , Arun, Banu , Gligorov, Joseph , Elghazawy, Hagar I , El Saghir, Nagi S , Perez, Edith A , Conte, Pierfranco , Tripathy, Debasish , Rugo, Hope S. , Cameron, David , Swain, Sandra M. , Harbeck, Nadia , Cardoso, Fátima , Gligorov, Joseph , Penault-Llorca, Frederique Madeleine , Kassem, Loay Mohamed Hassan , Al‐Sukhun, Sana , Abdelkarim, Khaled , Conte, PierFranco , Selim, Ashraf S. M. , Палтуев, Руслан Маликович , Abdel‐Aziz, Ahmed M.

Cancer | July 10, 2024 | Volume: 130 | Issue: 19 | Pages: 3251-3271

10.1002/cncr.35389 | PMID 38985794 Get It

AbstractBackgroundThe management of early breast cancer (BC) has witnessed an uprise in the use of neoadjuvant therapy and a remarkable reshaping of the systemic therapy postneoadjuvant treatment in the last few years, with the evolution of many controversial clinical situations that require consensus.MethodsDuring the 14th Breast‐Gynecological and Immuno‐Oncology International Cancer Conference held in Egypt in 2022, a panel of 44 BC experts from 13 countries voted on statements concerning debatable challenges in the neo/adjuvant treatment setting. The recommendations were subsequently updated based on the most recent data emerging. A modified Delphi approach was used to develop this consensus. A consensus was achieved when ≥75% of voters selected an answer.Results and ConclusionsThe consensus recommendations addressed different escalation and de‐escalation strategies in the setting of neoadjuvant therapy for early BC. The recommendations recapitulate the available clinical evidence and expert opinion to individualize patient management and optimize therapy outcomes. Consensus was reached in 63% of the statements (52/83), and the rationale behind each statement was clarified.
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US
Paly, Victoria Federico , Bekaii‐Saab, Tanios , Padukkavidana, Thihan, Hernández, Luis , Hernandez, Luis , Bekaii-Saab, Tanios S , Dasari, Arvind , Hubbard, Joleen M.

Journal of Comparative Effectiveness Research | July 10, 2024 | Volume: 13 | Issue: 8 | Pages: No page available

10.57264/cer-2024-0084 | PMID 38976346 Get It

Aim: The objective of this study was to compare adverse event (AE) management costs for fruquintinib, regorafenib, trifluridine/tipiracil (T/T) and trifluridine/tipiracil+bevacizumab (T/T+bev) for patients with metastatic colorectal cancer (mCRC) previously treated with at least two prior lines of therapy from the US commercial and Medicare payer perspectives. Materials & methods: A cost-consequence model was developed to calculate the per-patient and per-patient-per-month (PPPM) AE costs using rates of grade 3/4 AEs with incidence ≥5% in clinical trials, event-specific management costs and duration treatment. Anchored comparisons of AE costs were calculated using a difference-in-differences approach with best supportive care (BSC) as a common reference. AE rates and treatment duration were obtained from clinical trials: FRESCO and FRESCO-2 (fruquintinib), RECOURSE (T/T), CORRECT (regorafenib) and SUNLIGHT (T/T, T/T+bev). AE management costs for the commercial and Medicare perspectives were obtained from publicly available sources. Results: From the commercial perspective, the AE costs (presented as per-patient, PPPM) were: $4015, $1091 for fruquintinib (FRESCO); $4253, $1390 for fruquintinib (FRESCO-2); $17,110, $11,104 for T/T (RECOURSE); $9851, $4691 for T/T (SUNLIGHT); $8199, $4823 for regorafenib; and $11,620, $2324 for T/T+bev. These results were consistent in anchored comparisons: the difference-in-difference for fruquintinib based on FRESCO was -$1929 versus regorafenib and -$11,427 versus T/T; for fruquintinib based on FRESCO-2 was -$2257 versus regorafenib and -$11,756 versus T/T. Across all analyses, results were consistent from the Medicare perspective. Conclusion: Fruquintinib was associated with lower AE management costs compared with regorafenib, T/T and T/T+bev for patients with previously treated mCRC. This evidence has direct implications for treatment, formulary and pathways decision-making in this patient population.
Dopamine Dressing: AJR Podcast Series on Wellness, Episode 4
Wang, Sherry S.

American Journal of Roentgenology | July 10, 2024 | Volume: 223 | Issue: 2 | Pages: No page available

10.2214/ajr.24.31697 | PMID 38984782 Get It

Training and Verification Requirements for Interpretation of Cardiac CT and MRI: AJR Expert Panel Narrative Review
Morris, Michael F. , Ocazionez-Trujillo, Daniel , Ordovás, Karen , Ranganath, Praveen , Vargas, Daniel , Woodard, Pamela K. , Choi, Andrew , Rajiah, Prabhakar Shantha, Rajiah, Prabhakar , Budoff, Matthew J. , Ghoshhajra, Brian , Patel, Amit R.

American Journal of Roentgenology | July 10, 2024 | Volume: 224 | Issue: 3 | Pages: No page available

10.2214/ajr.24.31524 | PMID 38984783 Get It

Percutaneous Aspiration and Sclerotherapy as Primary Management for a Symptomatic Benign Adrenal Cyst
Strikwerda, John R. , McKenzie, Travis J. , Foster, Trenton R. , Bancos, Irina , Foster, Trenton R , Thompson, Scott M. , Shah, Mithun V , Bancos, Irina

JCEM Case Reports | July 10, 2024 | Volume: 2 | Issue: 7 | Pages: No page available

10.1210/jcemcr/luae110 | PMID 38989269 Get It

Abstract Adrenal cysts are a rare benign adrenal pathology. Although the majority of adrenal cysts are asymptomatic, large cysts may present with debilitating symptoms of mass effect. Surgical adrenalectomy or cyst fenestration has been the primary mode of management for such symptomatic cysts, but these interventions can be associated with excessive morbidity, particularly when considered in the context of benign disease. Here, we present a case of a 34-year-old female with a longstanding, growing, benign left adrenal cyst associated with nonspecific abdominal symptoms. After multidisciplinary discussion, the patient was managed with primary ultrasound/fluoroscopic guided percutaneous sclerotherapy of her adrenal cyst. This technique achieved complete cyst resolution that was durable on 7-month follow-up and was associated with significant improvement of the patient's symptoms. This case illustrates the potential for primary percutaneous sclerotherapy for primary management of benign adrenal cysts.
Gyratory seizures as a manifestation of possible generalized epilepsy
Ortiz‐Guerrero, Gloria , Ortiz, Judit Perez , Saify, Mariya , Selcen, Duygu , Fine, Anthony L. , Perez-Ortiz, Judit M, Fine, Anthony , Ortiz-Guerrero, Gloria

Epileptic Disorders | July 10, 2024 | Volume: 26 | Issue: 5 | Pages: 718-720

10.1002/epd2.20247 | PMID 38984496 Get It

Content available: Video
Fibula Free Flap Reconstruction of Cervical Spine Defects: A Multi‐Institutional Study
Yang, Sara , Morton, Zoey , Colcord, Maddie, Moore, Eric J. , Thuener, Jason E. , Bewley, Arnaud F. , Coughlin, Andrew, Richmon, Jeremy D. , Pipkorn, Patrik , Zender, Chad , Wax, Mark K. , Moore, Eric J , Thuener, Jason , Richmon, Jeremy D , Zender, Chad A , Wax, Mark K , Jackson, Ryan S. , Khariwala, Samir S , Winters, Ryan D. , Militsakh, Oleg N. , III, James M. Wright

The Laryngoscope | July 10, 2024 | Volume: 134 | Issue: 12 | Pages: 4923-4928

10.1002/lary.31625 | PMID 38984420 Get It

IntroductionCervical spine defects result in spinal instability, putting the spinal cord and vertebral arteries at risk of damage and possibly devastating neurological injuries. The fibula free flap can span the spinal defects for stability. There is a paucity of literature on this technique.MethodMulti‐institutional retrospective case series reviewing patients who underwent cervical spine reconstruction with a fibula free flap. Patient demographic information, comorbidities, characteristics of cervical spine defects, and free flap complications were collected.ResultsA total of 1187 fibula free flaps across 10 different institutions were reviewed. Thirteen patients (1.09%) underwent cervical spine reconstruction with a fibula free flap. Average age was 52.3 years old with an age range of 12–79 years. There were six males (46.1%) and seven females (53.8%). The most common defect etiology was infection (n = 6, 46.1%). Most commonly involved cervical spine level of the defect was C5 (n = 10) followed by C6 (n = 9) and C4 (n = 8). The majority of reconstructed defects spanned three or more cervical levels, (n = 9, 69.2%). Facial artery was the most common arterial anastomosis (n = 8). Eight patients (61.5%) required a tracheostomy during their postoperative course. None of the patients had symptomatic or radiographic nonunion.ConclusionThis case series demonstrates that a vascularized fibula flap is a potential reconstructive option for cervical spine defects, especially in defects greater than three cervical levels, in the setting of infection, and previously radiated patients.Level of Evidence4 Laryngoscope, 134:4923–4928, 2024
Toxic epidermal necrolysis‐like cutaneous toxicity following chimeric antigen receptor T‐cell therapy in recurrent large B‐cell lymphoma
Bhullar, Puneet , Zieman, Daniel, Johnson, Cassandra, Gurnani, Pooja , Sokumbi, Olayemi , Bhullar, Puneet K , Motaparthi, Kiran , Zieman, Daniel P, Sokumbi, Olayemi

Journal of Cutaneous Pathology | July 10, 2024 | Volume: 51 | Issue: 10 | Pages: 767-772

10.1111/cup.14687 | PMID 38982730 Get It

AbstractChimeric antigen receptor (CAR) T‐cell therapy has demonstrated remarkable success in treating various B‐cell malignancies, redirecting T‐cell cytotoxicity toward cancer cells. Despite its efficacy, CAR‐T therapy is associated with potential risks, including cytokine release syndrome (CRS) and cytopenia. We present a case of a 69‐year‐old man with diffuse large B‐cell lymphoma treated with axicabtagene‐ciloleucel CAR‐T therapy, who developed a rare and severe cutaneous toxicity resembling toxic epidermal necrolysis (TEN). The patient exhibited persistent fevers, CRS, and subsequent development of a widespread erythematous macular eruption, progressing to vesiculation with bullae. Notably, allopurinol‐induced TEN was considered with the patient's recent exposure to allopurinol, although the onset and minimal mucosal involvement did not align with typical presentations of allopurinol‐induced cases. The cutaneous reaction, distinct from typical SJS/TEN, showed minimal mucosal involvement and coincided with the cytokine release storm, differing from allopurinol‐induced TEN. Despite the absence of guidelines, the patient was managed with systemic steroids, achieving significant improvement. This case expands the spectrum of CAR‐T therapy‐related cutaneous toxicities, highlighting the need for early recognition of histopathology and tailored management by dermatologists. Further understanding of these reactions is crucial for optimizing the safety profile of this groundbreaking immunotherapy.
Clinical recognition of frontotemporal dementia with right anterior temporal predominance: A multicenter retrospective cohort study
Ulugut, Hülya , Samancı, Bedia , Illán‐Gala, Ignacio , Kuchcinski, Grégory , Leroy, Mélanie , Santillo, Alexander , Waldö, Maria Landqvist , Riedl, Lina , Stock, Jan Van den , Vandenbulcke, Mathieu , Ducharme, Simon , Pressman, Peter , Takada, Leonel Tadao , Diehl‐Schmid, Janine , Galimberti, Daniela , Barkhof, Frederik , Sturm, Virginia E. , Miyagawa, Toji , Whitwell, Jennifer L. , Rohrer, Jonathan D. , Gorno‐Tempini, Maria Luisa, Josephs, Keith A. , Warren, Jason D. , Rankin, Katherine P. , Group, International rtvFTD Working, Barkhof, Frederik , Rohrer, Jonathan D , Illán-Gala, Ignacio , Galimberti, Daniela , Bertoux, Maxime , Younes, Kyan , Montembeault, Maxime , Fumagalli, Giorgio , Thompson, J. C. , Kobylecki, Christopher , Englund, Elisabet , Vandenberghe, Rik , Laforce, Robert , Caramelli, Paulo , Souza, Leonardo Cruz de , Gurvit, Hakan I. , Hansson, Oskar , Pasquier, Florence , Miller, Bruce L. , Scheltens, Philip , Ossenkoppele, Rik , Flier, Wiesje M. van der , Fox, Nick C. , Boeve, Bradley F. , Gorno‐Tempini, Maria‐Luisa, Snowden, Julie S. , Pijnenburg, Yolande A.L. , Group, International rtvFTD Working

Alzheimer's & Dementia | July 10, 2024 | Volume: 20 | Issue: 8 | Pages: 5647-5661

10.1002/alz.14076 | PMID 38982845 Get It

Abstract INTRODUCTION Although frontotemporal dementia (FTD) with right anterior temporal lobe (RATL) predominance has been recognized, a uniform description of the syndrome is still missing. This multicenter study aims to establish a cohesive clinical phenotype. METHODS Retrospective clinical data from 18 centers across 12 countries yielded 360 FTD patients with predominant RATL atrophy through initial neuroimaging assessments. RESULTS Common symptoms included mental rigidity/preoccupations (78%), disinhibition/socially inappropriate behavior (74%), naming/word‐finding difficulties (70%), memory deficits (67%), apathy (65%), loss of empathy (65%), and face‐recognition deficits (60%). Real‐life examples unveiled impairments regarding landmarks, smells, sounds, tastes, and bodily sensations (74%). Cognitive test scores indicated deficits in emotion, people, social interactions, and visual semantics however, lacked objective assessments for mental rigidity and preoccupations. DISCUSSION This study cumulates the largest RATL cohort unveiling unique RATL symptoms subdued in prior diagnostic guidelines. Our novel approach, combining real‐life examples with cognitive tests, offers clinicians a comprehensive toolkit for managing these patients. Highlights This project is the first international collaboration and largest reported cohort. Further efforts are warranted for precise nomenclature reflecting neural mechanisms. Our results will serve as a clinical guideline for early and accurate diagnoses.
Graft Type and Diameter Are Predictors of Reinjury After Transphyseal Anterior Cruciate Ligament Reconstruction in Pediatric and Adolescent Patients
Schilaty, Nathan D. , Levy, Bruce A. , Milbrandt, Todd A. , Stuart, Michael J. , Krych, Aaron J. , Rigamonti, Luca , Milbrandt, Todd, Krych, Aaron J , Stuart, Michael J , Schilaty, Nathan D , Rigamonti, L , Bates, Nathaniel A. , Bigoni, Marco

Arthroscopy, Sports Medicine, and Rehabilitation | July 9, 2024 | Volume: 6 | Issue: 5 | Pages: No page available

10.1016/j.asmr.2024.100964 | PMID 39534033 Get It

Purpose To report the rate of anterior cruciate ligament (ACL) graft failure by physis status (open, closing, closed) and to analyze which factors were associated with higher risk of ACL graft failure. Methods Patients younger than 18 years who underwent transphyseal ACL reconstruction (ACLR) between 2000 and 2018 at a single institution were reviewed at minimum 2 years after ACLR. Patient records were reviewed for anthropometrics, surgical techniques, and ACL graft failure. Patients were subsequently stratified based on physis status (open, closing, closed) and analyzed. Results A total of 272 patients (mean age of 15.4 ± 1.3 years) were assessed. The transtibial technique was used in 63.6% of cases. A hamstring autograft was used exclusively in the open physis group. A patellar tendon autograft was used in 65.9% of patients with a closing physis and 80.9% of patients with a closed physis. The overall graft failure rate was 13.2%, with a contralateral ACL injury rate of 11.0%. Kaplan‐Maier analysis by physis status showed different injury free from ACL reinjury ( P < .001). An open physis was associated with increased risk of ACL reinjury (hazard ratio, 5.2; P < .001) when compared to a closed physis. A closing physis presented a higher hazard ratio but was not statistically significant (hazard ratio, 2.6; P = .08). Hamstring graft type ( P = .03) and lower graft diameter ( P = .04) were significantly related to higher ACL reinjury after adjusting for physis status. Conclusions Transphyseal ACLR is a safe procedure in pediatric patients. The rate of reinjury was 13.2%. This rate decreases with skeletal maturity, use of patellar tendon autograft, and a larger graft diameter. Level of Evidence Level III, retrospective cohort study.